Evidence map›Paper›PMID 40185987›Full record

ArticleCell biochemistry and biophysics2025

CircARID1B Promotes MPP

Xuejie Zhang, Xuan Shi, Zhining Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xuejie ZhangDepartment of Neurology, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, China.
Xuan ShiDepartment of Gastroenterology, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, China.
Zhining LiuDepartment of Ultrasound, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, China. jzykdx20130128@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence has shown the involvement of abnormal circRNA in neurodegenerative disease progression, including Parkinson's disease (PD). Hence, this work focused on probing the function and mechanism of circARID1B on PD progression.1-Methyl-4-phenylpyridinium (MPP+)-induced human dopaminergic SK-N-AS neuroblastoma cell models were used to mimic PD injury in vitro. qRT-PCR and western blotting analyses were used to detect the levels of genes and proteins. Cell death was evaluated by cell counting kit-8 assay, flow cytometry, and lactate dehydrogenase (LDH) activity. Oxidative stress was analyzed by measuring the production of reactive oxygen species (ROS) and superoxide dismutase (SOD). Cell inflammation was determined by ELISA analysis. The binding between miR-143-3p and circARID1B or mitochondrial antiviral signaling protein (MAVS) was analyzed by dual-luciferase reporter and RNA immunoprecipitation assays. A high circARID1B expression was observed in MPP

Indexed as

1-Methyl-4-phenylpyridiniumAdaptor Proteins, Signal TransducingDopaminergic NeuronsMicroRNAsRNA, CircularApoptosisCell Line, TumorHumansInflammationOxidative StressReactive Oxygen Species1-Methyl-4-phenylpyridiniumAdaptor Proteins, Signal TransducingMicroRNAsMIRN143 microRNA, humanReactive Oxygen SpeciesRNA, CircularcircARID1BLDHMAVSmiR-143-3pOxidative stressParkinson’s disease

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.